Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Debt (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Total Debt for 12 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 26.37% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, down 26.37% year-over-year, with the annual reading at $37.1 million for FY2025, 26.37% down from the prior year.
  • Total Debt hit $37.1 million in Q4 2025 for Coherus Oncology, roughly flat from $37.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $250.3 million in Q3 2023 to a low of $36.9 million in Q2 2025.
  • Historically, Total Debt has averaged $128.2 million across 5 years, with a median of $75.1 million in 2021.
  • Biggest five-year swings in Total Debt: skyrocketed 225.99% in 2022 and later crashed 81.69% in 2024.
  • Year by year, Total Debt stood at $75.5 million in 2021, then surged by 225.09% to $245.5 million in 2022, then rose by 1.75% to $249.8 million in 2023, then plummeted by 79.86% to $50.3 million in 2024, then decreased by 26.37% to $37.1 million in 2025.
  • Business Quant data shows Total Debt for CHRS at $37.1 million in Q4 2025, $37.0 million in Q3 2025, and $36.9 million in Q2 2025.